Welcome to our dedicated page for Horizon Therapeutics Pub L news (Ticker: HZNP), a resource for investors and traders seeking the latest updates and insights on Horizon Therapeutics Pub L stock.
Horizon Therapeutics plc (NASDAQ: HZNP) is a global biotechnology leader focused on developing therapies for rare, autoimmune, and severe inflammatory diseases. This dedicated news hub provides investors and healthcare professionals with timely updates on regulatory milestones, research breakthroughs, and strategic corporate initiatives shaping the company's trajectory.
Access authoritative information on Horizon's innovative treatments like TEPEZZA® and KRYSTEXXA®, along with analysis of key developments including partnership announcements and regulatory filings. Our curated news collection serves as your primary resource for understanding Horizon's position in the biopharmaceutical landscape and its commitment to addressing unmet medical needs.
Key updates cover clinical trial progress, FDA communications, financial results, and major corporate events such as Horizon's pending acquisition by Amgen following FTC clearance. All content is sourced from official releases and verified channels to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to Horizon Therapeutics' evolving story. For additional context on the company's mission and pipeline, visit their official website at HorizonTherapeutics.com.
Horizon Therapeutics plc (NASDAQ: HZNP) has released a Rule 8.1 dealing disclosure under the Irish Takeover Panel Act. The disclosure pertains to Timothy P. Walbert, a person acting in concert with the offeree (as a director of Horizon Therapeutics). On June 1, 2023, Walbert purchased 279 ordinary shares at a price of $76.07 per unit.
Following this transaction, Walbert owns or controls 3,737,295 ordinary shares, representing 1.633% of the company's relevant securities. The disclosure also corrects a previous error in the January 6, 2023 Rule 8.1 Disclosure, which incorrectly stated Walbert's ownership as 3,620,605 shares. The correct number of shares owned on January 5, 2023, was 3,737,016.
